ROSSARI Q2: CONS NET PROFIT AT ₹38.9 CR; REVENUE UP 19% YOY. MIX (ON 1ST LOOK)

Revenue up 19.0% at ₹697.6 Cr (YOY); H1 revenue up 23.4% at ₹1,394.8 Cr. Ebitda up 20.9% at ₹87.0 Cr (YOY); margins 12.5%, up 20 bps (YOY). H1 Ebitda ₹167.6 Cr, up 19.9% (YOY); H1 margins 12.0%, down 40 bps. Export sales ₹216.4 Cr, up 33.8% (YOY); net debt ₹221 Cr v ₹281 Cr (Mar 2026). Caution: PAT subdued due to higher depreciation from long-term project investments.

Rossari Biotech Limited

Open attachment

← Back to feed